Answers are grounded in this paper and cite their sources.
Collectively, the results provide novel evidence that IN administration of therapeutic hiPSC-NSC-EVs is an efficient avenue for directing such EVs into neurons and glia in all brain regions in the early stage of amyloidosis. As pathological changes in AD are observed in multiple brain areas, the ability to deliver therapeutic EVs into various neural cells in virtually every brain region in the early stage of amyloidosis is attractive for promoting neuroprotective and antiinflammatory effects.
No takes yet. Share an insight, caveat, or question.
Attaluri et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: